

10th Euro-Global Conference on **Infectious Diseases** & 5th International Conference on **Histopathology & Cytopathology**

September 27-29, 2018 Rome, Italy

Assessing the quality of antimalarial drugs from india using minilab: A field study

Taruna Arora and Neena Valecha

National Institute of Malaria Research, India

Substandard and counterfeit antimalarial medicines poses a serious threat to public health. These medicines increases the mortality by decreasing efficacy; it also increases the threat of emergence of drug resistance, adverse effect from incorrect excipients/ active ingredients which may be potentially dangerous to the patients. Owing to this, a pilot study was conducted to survey quality of drugs collected from different malaria endemic areas of India. The survey was conducted in different geographical regions on the basis of malaria endemicity i.e. Uttar Pradesh (U.P.), Mizoram, Meghalaya, Gujarat, Madhya Pradesh. A mystery shopper approach was used for collection of samples. The quality of antimalarial drugs from these areas were assessed by using Global Pharma Health Fund Minilab test kit. This includes physical/visual inspection and disintegration test, thin-layer chromatography. High performance liquid chromatography was carried out for quantitative assessment of active pharmaceutical ingredient. A total of 150 antimalarial samples were collected. These samples includes 55 (Chloroquine), 50 (Artemether Lumefantrine), 14 (Artesunate Sulphadoxine-Pyrimethamine), 31 (Primaquine). These samples were assessed by quality using GPHF minilab lab kit. In this study 98% of the tablets passed minilab disintegration, 2% consisting did not passed disintegration test. 99% of samples passed preliminary Qualitative TLC test when compared with 100% and 80% of the standards. 96% of samples passed quantitative HPLC test, 4% of samples (contained low active pharmaceutical ingredient) did not passed this test. The substandard drugs circulating in the market causes drug resistance, treatment failure and finally leads to death. Additional analysis such as post-marketing surveillance should be done so that good quality antimalarials reached to the population.

Biography

Taruna Arora has completed PhD at the age of 30 years from Uttarakhand Technical University, Dehradun and Post-doctoral studies from National Institute of Malaria Research, New Delhi, India. She has published more than 14 papers in reputed Journals. She is the member of many societies like Pharmacy Council of India (PCI), Indian Pharmacological Society (IPS), Society of Biomedical Laboratory Scientists, India (SOBLI).

tarunakaty@gmail.com

Notes: